0
0
April 23, 2025 – Widely used weight loss medications like Ozempic and Mounjaro are facing fresh scrutiny following a new study suggesting a potential link to mental health issues, including depression and suicidal thoughts. The research, published in Current Neuropharmacology, raises concerns about how these drugs, known as GLP-1 receptor agonists, might affect brain chemistry.
Originally developed for managing type 2 diabetes, drugs like Ozempic and Mounjaro have surged in popularity for off-label use in weight management. They work by mimicking a natural hormone, incretin, activating GLP-1 receptors in the brain to signal fullness, reduce appetite, and regulate blood sugar. While many users report success in weight loss, these medications are known to have potential side effects.
Common physical side effects include nausea, vomiting, diarrhoea, and fatigue. More serious, though rarer, risks like kidney problems, pancreatitis, gallbladder issues, vision loss, and even thyroid tumours have also been documented.
This latest study adds potential mental health risks to the list. Researchers found evidence that GLP-1 agonists may interact with genes crucial for mood regulation and dopamine signalling – specifically DRD3, BDNF, and CREB1. These genes have established links to depression, anxiety, and suicidal ideation.
The study suggests that by potentially disrupting dopamine pathways, chronic use of these drugs could increase the risk of mood disorders. “Chronic use may disrupt dopamine signalling and increase the risk of depression and suicidal thoughts,” the researchers warned. They noted that while the drugs might potentially benefit those with excessive dopamine activity (hyperdopaminergic conditions), they could pose risks for individuals with naturally low dopamine levels, potentially worsening mental health.
Experts involved in the study are urging caution. “This study should not be ignored, despite the hype surrounding the positive clinical outcomes of GLP-1 receptor agonists,” stated senior author Dr. Kenneth Blum of Western University Health Sciences and Ariel University.
Co-author Dr. Mark S. Gold, an addiction psychiatry expert, added, “The paper provides critical evidence for reevaluating the widespread use of GLP-1 receptor agonists. The FDA and other regulatory agencies should carefully consider our findings.”
For individuals seeking non-pharmacological methods to manage appetite and weight, experts often recommend lifestyle strategies:
- Boost Protein and Fibre Intake: Foods like eggs, beans, lentils, nuts, and whole grains promote satiety.
- Stay Hydrated: Drinking water, especially before meals, can help manage hunger cues.
- Practice Mindful Eating: Paying attention to meals, eating slowly, and avoiding distractions helps recognise fullness.
- Prioritise Sleep: Adequate sleep helps regulate hunger hormones like ghrelin and leptin.
- Manage Stress: Techniques like meditation, deep breathing, or exercise can curb stress-induced eating.
- Engage in Regular Exercise: Physical activity aids metabolism, burns calories, and improves mood.
The new findings emphasize the importance of thorough discussion between patients and healthcare providers regarding the full spectrum of potential risks and benefits associated with GLP-1 agonist medications.
Disclaimer: This news article is based on information from a recent study and expert opinions. It is intended for informational purposes only and does not constitute medical advice. Individuals considering or currently using GLP-1 agonists like Ozempic or Mounjaro should consult with their healthcare provider to discuss potential benefits, risks, side effects, and alternatives based on their personal health history and specific circumstances. Do not stop or change your medication regimen without consulting your doctor.
https://www.timesnownews.com/health/think-twice-before-using-ozempicnew-study-links-it-to-mood-disorders-and-brain-changes-article-151473466
